ClinicalTrials.gg

Ipsen clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 357 studies whose lead sponsor is Ipsen or one of 7 companies grouped under it. 24 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 13, 2026.

Our grouping of 8 registry names, not the registry’s. See them and correct one ↓

Compare Ipsen with Johnson & Johnson and Sichuan Biokin Pharmaceutical →

Pipeline: 8 programs

Each counted once: 8 with a study Ipsen leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3

The 4 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Ipsen’s own registered studies; Ipsen’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Ipsen’s studies test, most open studies first — 53 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 53; every drug is on its own page, and each page lists its sponsors.

Coming up

16 of Ipsen’s studies under way reach primary completion within a year, 6 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 1N’26
  2. 4D
  3. J’27
  4. 3F
  5. 2M
  6. A
  7. M
  8. J
  9. J
  10. 1A
  11. 1S
  12. 3O
  13. 1N

The 12 nearest

Show 7 more

Add all 16 to your calendar (.ics) → With an account.

All 357 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now247%Recruiting 22 · Not yet recruiting 2
  • Under way, not recruiting226%
  • Completed23967%
  • Stopped early6618%Terminated 55 · Withdrawn 11
  • Status unknown or other62%Status unknown 3 · No longer available 3

Phase

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 2614
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 1326

By the year each study started; 50 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Ipsen.

  • Ipsen
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    289 studies
  • Epizyme, Inc.
    Acquired — became part of Ipsen, Aug 12, 2022 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    21 studies →
  • Kartos Therapeutics, Inc.
    Acquired — became part of Ipsen, Aug 21, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    16 studies →
  • Albireo
    Acquired — became part of Ipsen, Mar 2, 2023 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    11 studies →
  • Clementia Pharmaceuticals Inc.
    Acquired — became part of Ipsen, Apr 18, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    10 studies →
  • Albireo, an Ipsen Company
    Acquired — became part of Ipsen, Mar 2, 2023 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • Memo Therapeutics AG
    Acquired — became part of Ipsen, Jul 22, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • ImCheck Therapeutics, an Ipsen company
    Acquired — became part of Ipsen, Dec 15, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →

Focus areas

Conditions Ipsen leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 357. Browse all 357 →